
Sign up to save your podcasts
Or
Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.
4.8
2626 ratings
Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.
138 Listeners
116 Listeners
26,369 Listeners
28 Listeners
184 Listeners
2 Listeners
367 Listeners
53 Listeners
372 Listeners
136 Listeners
9 Listeners
29 Listeners
185 Listeners
49 Listeners
43 Listeners